RxDoctor Payments DataLook up a doctor →

Colleen Barry

Family · Bowling Green, OHNPI 1023498623

Payments from drug & device makers

$31,398in general payments, 2019–2025

Across 505 payments — averaging $62.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$16K
  • Gilead$4K
  • AbbVie$3K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$916
  • Axsome Therapeutics, Inc.$760
  • plus $6K from 36 others

What the payments were for

  • Consulting fees$2,3908%
  • Speaking & faculty fees$13,38043%
  • Travel & lodging$1,8206%
  • Food & beverage$13,73644%
  • Education$720%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,398 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$5,626
Medicare patients
30
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate65$39,165
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$28,492
JardianceEmpagliflozin22$22,882
Breo ElliptaFluticasone/Vilanterol50$20,269
VivitrolNaltrexone Microspheres11$19,523
TrulicityDulaglutide18$18,196
FarxigaDapagliflozin Propanediol16$11,286
SuboxoneBuprenorphine Hcl/Naloxone Hcl13$4,469
Atorvastatin Calcium391$2,185
Albuterol Sulfate HfaAlbuterol Sulfate61$1,548
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$1,514
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$1,499
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl37$1,436
Lisinopril176$1,306
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$85$48,76087 claims
Boehringer IngelheimJardiance$98$22,88222 claims
Alkermes, Inc.Vivitrol$16,312$19,52311 claims
Indivior Inc.Suboxone$494$4,46913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Bowling Green

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →